75 related articles for article (PubMed ID: 20422369)
1. Enhanced effect of losartan and rosuvastatin on neointima hyperplasia.
Yi I; Lee JJ; Park JS; Zhang WY; Kim IS; Kim Y; Shin CY; Kim HS; Myung CS
Arch Pharm Res; 2010 Apr; 33(4):593-600. PubMed ID: 20422369
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat.
van der Harst P; Groenewegen HC; Roks AJ; Buikema H; Zijlstra F; van Gilst WH; de Smet BJ
Coron Artery Dis; 2008 Feb; 19(1):47-53. PubMed ID: 18281816
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
Kang BY; Mehta JL
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Schäfer K; Kaiser K; Konstantinides S
Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
[TBL] [Abstract][Full Text] [Related]
5. GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster.
Matsuno H; Kozawa O; Niwa M; Kaida T; Hayashi H; Uematsu T
Br J Pharmacol; 1997 Nov; 122(6):1099-104. PubMed ID: 9480031
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory effects of irbesartan with rosuvastatin on vascular remodeling.
Ohshima K; Mogi M; Nakaoka H; Jing F; Iwanami J; Min LJ; Tsukuda K; Kanno H; Ogimoto A; Higaki J; Horiuchi M
J Am Soc Hypertens; 2012; 6(6):375-84. PubMed ID: 23107893
[TBL] [Abstract][Full Text] [Related]
7. Neointimal-specific induction of apoptosis by losartan results in regression of vascular lesion in rat aorta.
Lemay J; Hale TM; deBlois D
Eur J Pharmacol; 2009 Sep; 618(1-3):45-51. PubMed ID: 19619526
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of rosuvastatin on aortic adverse remodeling in nitric oxide-deficient rats.
Neto-Ferreira R; Novaes Rocha V; da Silva Torres T; Mandarim-de-Lacerda CA; de Carvalho JJ
Exp Toxicol Pathol; 2011 Jul; 63(5):473-8. PubMed ID: 20537513
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor.
Kiyan J; Kusch A; Tkachuk S; Krämer J; Haller H; Dietz R; Smith G; Dumler I
Atherosclerosis; 2007 Dec; 195(2):254-61. PubMed ID: 17275828
[TBL] [Abstract][Full Text] [Related]
10. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin.
Ajith TA; Riji T; Anu V
Clin Exp Pharmacol Physiol; 2008 May; 35(5-6):625-9. PubMed ID: 18177480
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein lowering with rosuvastatin in the METEOR study.
Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice.
Li W; Asagami T; Matsushita H; Lee KH; Tsao PS
J Pharmacol Exp Ther; 2005 May; 313(2):557-62. PubMed ID: 15665143
[TBL] [Abstract][Full Text] [Related]
13. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
[TBL] [Abstract][Full Text] [Related]
14. Rapid response to lipids profile and leukocyte gene expression after rosuvastatin administration in Chinese healthy volunteers.
Hua CX; Li YS; Liu YQ; Liu H; Li N; Wu Y; Xu L; Huang YL
Chin Med J (Engl); 2008 Jul; 121(13):1215-9. PubMed ID: 18710642
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
16. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
Simonson SG; Martin PD; Mitchell PD; Lasseter K; Gibson G; Schneck DW
J Clin Pharmacol; 2005 Aug; 45(8):927-34. PubMed ID: 16027403
[TBL] [Abstract][Full Text] [Related]
17. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
Sicard P; Lauzier B; Oudot A; Busseuil D; Collin B; Duvillard L; Moreau D; Vergely C; Rochette L
Arch Mal Coeur Vaiss; 2005; 98(7-8):804-8. PubMed ID: 16220751
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
19. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Kilic U; Bassetti CL; Kilic E; Xing H; Wang Z; Hermann DM
Neuroscience; 2005; 134(3):901-6. PubMed ID: 16009498
[TBL] [Abstract][Full Text] [Related]
20. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
